Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.75 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.75 |
| ▸ | TNF | P01375 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | GALR3 | O60755 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907295 | 0.91 | CYP11B1 (0.89) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL230002 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL31357411 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL8325011 | 0.85 | CYP11B1 (0.77) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL14042406 | 0.85 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL16147345 | 0.84 | HTT (0.77) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL2022520 | 0.83 | CYP11B1 (0.75) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL12203767 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL8070001 | 0.83 | CYP11B1 (0.75) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL9049676 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| CN-110256359-A | 2- aminobenzimidazole derivative and its synthesis and application | 武汉工程大学 | 2019-09-20 | — | — | CN | disclosed |
| EP-3514147-A1 | STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | University of Maryland, Baltimore (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-9694005-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694005-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-04 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | CYP11B1 403/4885CYP11B2 339/4885TNF 4799/4885 |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | AR, NR5A1, BRCA1 | CYP11B1 24/4885CYP11B2 52/4885TNF 2821/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | CYP11B1 24/4885CYP11B2 52/4885TNF 2821/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | CYP11B1 277/4885CYP11B2 183/4885TNF 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.